The complex interaction between overweight, hypertension, and sympathetic overactivity

Journal of the American Society of Hypertension

Volumn 3, Issue 6, 2009, Pages 353-365

  Feldstein, Carlos ^a   Julius, Stevo ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BETA ADRENERGIC RECEPTOR; LEPTIN; NORADRENALIN;

ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; CAUSAL ATTRIBUTION; DISEASE ASSOCIATION; ENERGY EXPENDITURE; ESSENTIAL HYPERTENSION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; HYPERKINESIA; HYPERTENSION; NONHUMAN; OBESITY; OVERNUTRITION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SLEEP APNEA SYNDROME; SYMPATHETIC TONE; TACHYCARDIA;

EID: 70549093287     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2009.10.001     Document Type: Review

References (157)

1. th ed (2006), WB Saunders, Philadelphia p 881-8
2. Landsberg L., Saville M.E., and Young J.B. Sympathoadrenal system and regulation of thermogenesis. Am J Physiol 247 2 Pt 1 (1984) E181-E189
3. Scherrer U., Randin D., Tappy L., Vollenweider P., Jéquier E., and Nicod P. Body fat and sympathetic nerve activity in healthy subjects. Circulation 89 (1994) 2634-2640
4. Poehlman E.T., Gardner A.W., Goran M.I., Arciero P.J., Toth M.J., Ades P.A., et al. Sympathetic nervous system activity, body fatness, and body fat distribution in younger and older males. J Appl Physiol 78 (1995) 802-806
5. Paolisso G., Manzella D., Ferrara N., Gambardella A., Abete P., Tagliamonte M.R., et al. Glucose ingestion affects cardiac ANS in healthy subjects with different amounts of body fat. Am J Physiol 273 3 Pt 1 (1997) E471-E478
6. Blaak E.E., van Baak M.A., Kempen K.P., and Saris W.H. Role of alpha- and beta- adrenoceptors in sympathetically mediated thermogenesis. Am J Physiol 264 1Pt 1 (1993) E11-E17
7. Sjöström L., Schutz Y., Gudinchet F., Hegnell L., Pittet P.G., and Jéquier E. Epinephrine sensitivity with respect to metabolic rate and other variables in women. Am J Physiol 245 5 Pt 1 (1983) E431-E442
8. Webber J., Taylor J., Greathead H., Dawson J., Buttery P.J., and Macdonald I.A. A comparison of the thermogenic, metabolic and haemodynamic responses to infused adrenaline in lean and obese subjects. Int J Obes Relat Metab Disord 18 (1994) 717-724
9. Welle S., Schwartz R.G., and Statt M. Reduced metabolic rate during beta-adrenergic blockade in humans. Metabolism 40 (1991) 619-622
10. Zurlo F., Larson K., Bogardus C., and Ravussin E. Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Clin Invest 86 (1990) 1423-1427
11. Ravussin E., and Bogardus C. A brief overview of human energy metabolism and its relationship to essential obesity. Am J Clin Nutr 55 (1992) 242S-245S
12. Simonsen L., Stallknecht B., and Bülow J. Contribution of skeletal muscle and adipose tissue to adrenaline-induced thermogenesis in man. Int J Obes. Relat Metab Disord 17 Suppl 3 (1993) S47-S51
13. Simonsen L., Bülow J., Madsen J., and Christensen N.J. Thermogenic response to epinephrine in the forearm and abdominal subcutaneous adipose tissue. Am J Physiol 263 5 Pt 1 (1992) E850-E855
14. Lean M.E. Brown adipose tissue in humans. Proc Nutr Soc 48 (1989) 243-256
15. Krief S., Lönnqvist F., Raimbault S., Baude B., Van Spronsen A., Arner P., et al. Tissue distribution of beta 3-adrenergic receptor mRNA in man. J Clin Invest 91 (1993) 344-349
16. Virtanen K., Lidell M., Orava J., Heglind M., Westergren R., Niemi T., et al. Functional brown adipose tissue in healthy adults. N Engl J Med 360 (2009) 1518-1525
17. van Marken Lichtenbeit W.D., Vanhommering J.W., Smulders N.M., Drossaerts J.M.A.F.L., Kemerink G.J., Bouvy N., et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med 360 (2009) 1500-1509
18. Acheson K.J., Ravussin E., Wahren J., and Jéquier E. Thermic effect of glucose in man. Obligatory and facultative thermogenesis. J Clin Invest 74 (1984) 1572-1580
19. Young J.B., and Landsberg L. Suppression of sympathetic nervous system during fasting. Science 196 (1977) 1473-1475
20. Young J.B., and Landsberg L. Stimulation of the sympathetic nervous system during sucrose feeding. Nature 269 (1977) 615-617
21. Landsberg L., and Young J.B. Diet and the sympathetic nervous system: relationship to hypertension. Int J Obes 5 (1981) 79-91
22. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 61 (1986) 1081-1090
23. Astrup A., Bülow J., Christensen N.J., Madsen J., and Quaade F. Facultative thermogenesis induced by carbohydrate: a skeletal muscle component mediated by epinephrine. Am J Physiol 250 2Pt 1 (1986) E226-E229
24. Schwartz R.S., Jaeger L.F., Silberstein S., and Veith R.C. Sympathetic nervous system activity and the thermic effect of feeding in man. Int J Obes 11 (1987) 141-149
25. Landsberg L., and Young J.B. Sympathoadrenal activity and obesity: physiological rationale for the use of adrenergic thermogenic drugs. Int J Obes Relat Metab Disord 17 Suppl 1 (1993) S29-S34
26. Landsberg L., and Young J.B. The role of the sympathoadrenal system in modulating energy expenditure. In: James W.P.T. (Ed). Clinics in endocrinology and metabolism obesity (1984), WB Saunders, London 475-499
27. Landsberg L., and Young J.B. Autonomic regulation of thermogenesis. In: Girardier L., and Stock M.J. (Eds). Mammalian thermogenesis (1983), Chapman and Hall, London 99-140
28. Young J.B., and Landsberg L. Impaired suppression of sympathetic activity during fasting in the gold thioglucose-treated mouse. J Clin Invest 65 (1980) 1086-1094
29. Rowe J.W., Young J.B., Minaker K.L., Stevens A.L., Pallotta J., and Landsberg L. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 30 (1981) 219-225
30. Hausberg M., Mark A.L., Hoffman R.P., Sinkey C.A., and Anderson E.A. Dissociation of sympathoexcitatory and vasodilator actions of modestly elevated plasma insulin levels. J Hypertension 13 (1995) 1015-1021
31. DeFronzo R.A., Thorin D., Felber J.P., Simonson D.C., Thiebaud D., Jequier E., et al. Effect of beta and alpha adrenergic blockade on glucose-induced thermogenesis in man. J Clin Invest 73 (1984) 633-639
32. Ward K.D., Sparrow D., Landsberg L., Young J.B., Vokonas P.S., and Weiss S.T. Influence of insulin, sympathetic nervous system activity, and obesity on blood pressure: the Normative Aging Study. J Hypertens 14 (1996) 301-308
33. Rumantir M.S., Vaz M., Jennings G.L., Collier G., Kaye D.M., Seals D.R., et al. Neural mechanisms in human obesity-related hypertension. J Hypertens 17 (1999) 1125-1133
34. Corry D.B., and Tuck M.L. Obesity, hypertension, and sympathetic nervous system activity. Curr Hypertens Rep 1 (1999) 119-126
35. Esler M., Lambert G., Brunner-La Rocca H.P., Vaddadi G., and Kaye D. Sympathetic nerve activity and neurotransmitter release in humans: translation from pathophysiology into clinical practice. Acta Physiol Scand 177 (2003) 275-284
36. Grassi G., Cattaneo B.M., Seravalle G., Colombo M., Cavagnini F., and Mancia G. Obesity and the sympathetic nervous system. Blood Press Suppl 1 (1996) 43-46
37. Lambert E., Straznicky N., Schlaich M., Esler M., Dawood T., Hotchkin E., et al. Differing pattern of sympathoexcitation in normal-weight and obesity-related hypertension. Hypertension 50 (2007) 862-868
38. Young J.B., Rosa R.M., and Landsberg L. Dissociation of sympathetic nervous system activity in the rat. Evidence for nutrient-specific responses. Am J Physiol 247 1 Pt 1 (1984) E35-E40
39. Goldstein D.S. Plasma catecholamines and essential hypertension: an analytical review. Hypertension 5 (1983) 86-99
40. Goldstein D.S. Catecholamines and stress. Endocr Regul 37 (2003) 69-80
41. Leonetti D.L., Bergstrom R.W., Shuman W.O., Wahl P.W., Jenner D.A., Harrison G.A., et al. Urinary catecholamines, plasma insulin and environmental factors in relation to body fat distribution. Int J Obes 15 (1991) 345-357
42. Widimsky J., Fejfarova M.H., and Fejfar Z. Changes of cardiac output in hypertensive disease. Cardiologia 31 (1957) 381-389
43. Eich R.H., Peters R.J., Cuddy R.P., Smulyan H., and Lyons R.H. Hemodynamics in labile hypertension. Am Heart J 63 (1962) 188-195
44. Finkielman S., Worcel M., and Agrest A. Hemodynamic patterns in essential hypertension. Circulation 31 (1965) 356-368
45. Bello C.T., Sevy R.W., and Harakal C. Varying hemodynamic patterns in essential hypertension. Am J Med Sci 250 (1965) 24-35
46. Eich R.H., Cuddy R.P., Smulyan H., and Lyons R.H. Hemodynamics in labile hypertension: follow-up study. Circulation 34 (1966) 299-307
47. Sannerstedt R. Hemodynamic response to exercise in patients with arterial hypertension. Acta Med Scand 180 Suppl. 458 (1966) 1-83
48. Lund-Johansen P. Twenty-year follow-up of hemodynamics in essential hypertension during rest and exercise. Hypertension 18 5 Suppl. (1991) 11154-11161
49. Julius S., Pascual A.V., and London R. Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation 44 (1971) 413-418
50. Julius S., and Conway J. Hemodynamic studies in patients with borderline blood pressure elevation. Circulation 38 (1968) 282-288
51. Esler M., Julius S., Zweifler A., Randall O., Harburg E., Gardiner H., et al. Mild high-renin essential hypertension. Neurogenic human hypertension?. New Engl J Med 296 (1977) 405-411
52. Levy R.L., White P.D., Stroud W.D., and Hillman C.C. Transient tachycardia: prognostic significance alone and in association with transient hypertension. JAMA 129 (1945) 585-588
53. Palatini P., and Julius S. Heart rate and the cardiovascular risk. J Hypertens 15 (1997) 3-17
54. Lund-Johansen P., and Omvik P. Hemodynamic patterns of untreated hypertensive disease. In: Laragh J.H., and Brenner B.M. (Eds). Hypertension: pathophysiology, diagnosis and management. 2nd ed (1995), Raven Press, New York 324-340
55. Julius S., Randall O.S., Esler M.D., Kashima T., Ellis C., and Bennet J. Altered cardiac responsiveness and regulation in the normal cardiac output type of borderline hypertension. Circulation Res 36 Suppl 1 (1975) 199-207
56. Egan B., Panis R., Hinderliter A., Schork N., and Julius S. Mechanism of increased alpha-adrenergic vasoconstriction in human essential hypertension. J Clin Invest 80 (1987) 812-817
57. Kjeldsen S.E., Zweifler A.J., Petrin J., Weder A.B., and Julius S. Sympathetic nervous system involvement in essential hypertension: increased platelet noradrenaline coincides with decreased beta-adrenoreceptor responsiveness (1994), Blood Press 3:164-71
58. Anderson E.A., Sinkey C.A., Lawton W.J., and Mark A.L. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension 14 (1989) 177-183
59. Grassi G., Cattaneo B.M., Seravalle G., Lanfranchi A., and Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 31 (1998) 68-72
60. Grassi G., Seravalle G., Trevano F.Q., Dell'oro R., Bolla G., Cuspidi C., et al. Neurogenic abnormalities in masked hypertension. Hypertension 50 (2007) 537-542
61. Esler M., Lambert G., Vaz M., Thompson J., Kaye D., Kalff V., et al. Central nervous system monoamine neurotransmitter turnover in primary and obesity-related human hypertension. Clin Exp Hypertens 19 (1997) 577-590
62. Grassi G., and Esler M. How to assess sympathetic activity in humans. J Hypertens 17 (1999) 719-734
63. Guzzetti S., Piccaluga E., Casati R., Cerutti S., Lombardi F., Pagani M., et al. Sympathetic predominance in essential hypertension: a study employing spectral analysis of heart rate variability. J Hypertens 6 (1988) 711-717
64. Grassi G., Vailati S., Bertinieri G., Seravalle G., Stella M.L., Dell'Oro R., et al. Heart rate as marker of sympathetic activity. J Hypertens 16 (1998) 1635-1639
65. Julius S., Krause L., Schork N.J., Mejia A.D., Jones K.A., van de Ven C., Johnson E.H., et al. Hyperkinetic borderline hypertension in Tecumseh. Michigan. J Hypertens 9 (1991) 77-84
66. Schork N.J., Weder A.B., Schork M.A., Bassett D.R., and Julius S. Disease entities, mixed multi-normal distributions, and the role of the hyperkinetic state in the pathogenesis of hypertension. Stat Med 9 (1990) 301-314
67. Palatini P., Casiglia E., Pauletto P., Staessen J., Kaciroti N., and Julius S. Relationship of tachycardia with high blood pressure and metabolic abnormalities. A study with mixture analysis in three populations. Hypertension 30 (1997) 1267-1273
68. Grassi G. Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions. J Hypertens 19 (2001) 1713-1716
69. Mancia G., Saino A., and Grassi G. Interactions between the sympathetic nervous system and the renin angiotensin system. In: Laragh J.H., and Brenner B.M. (Eds). Hypertension, pathophysiology, diagnosis, and management. 2nd ed (1995), Raven Press, Ltd, New York 399-407
70. Coote J.H., Johns E.J., Macleod V.H., and Singer B. Effect of renal nerve stimulation, renal blood flow and adrenergic blockade on plasma renin activity in the cat. J Physiol 226 (1972) 15-36
71. Kiowski W., and Julius S. Renin response to stimulation of cardiopulmonary mechanoreceptors in man. J Clin Invest 62 (1978) 656-663
72. Sweet C.S., Kadowitz P.J., and Brody M.J. Arterial hypertension elicited by prolonged intravertebral infusion of angiotensin II in conscious dog. Am J Physiol 221 (1971) 1640-1644
73. Andreatta S.H., Averill D.B., Santos R.A.S., and Ferrario C.M. The ventrolateral medulla. A new site of action of the renin-angiotensin system. Hypertension 11 Suppl I (1988) 163-166
74. Mark A.L., Abboud F.M., and Fitz A.E. Influence of low- and high-pressure baroreceptors on plasma renin activity in humans. Am J Physiol 235 (1978) H29-H33
75. Egan B.M., Julius S., Cottier C., Osterziel K.J., and Ibsen H. The role of cardiovascular receptors on the neural regulation of renin release in normal man. Hypertension 5 (1983) 779-786
76. Khairallah P.A. Action of angiotensin on adrenergic nerve endings: inhibition of norepinephrine uptake. Federation Proc 31 (1972) 1351-1357
77. Cline Jr. W.H. Enhanced in vivo responsiveness of presynaptic angiotensin II receptor-mediated facilitation of vascular adrenergic neurotransmission in spontaneously hypertensive rats. J Pharmacol Exp Ther 232 (1985) 661-669
78. Eikelis N., and Esler M. The neurobiology of human obesity. Exp Physiol 90 (2005) 673-682
79. Vaz M., Jennings G., Turner A., Cox H., Lambert G., and Esler M. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 96 (1997) 3423-3429
80. Rumantir M.S., Vaz M., Jennings G.L., Collier G., Kaye D.M., Seals D.R., et al. Neural mechanisms in human obesity-related hypertension. J Hypertens 17 (1999) 1125-1133
81. Rocchini A.P. The influence of obesity in hypertension. News Physiol Sci 5 (1990) 245-249
82. Hall J.E. The kidney, hypertension and obesity. Hypertension 41 (2003) 625-633
83. Hall J.E. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens 10 (1997) S49-S55
84. Schutz Y., Golay A., Felber J.P., and Jéquier E. Decreased glucose-induced thermogenesis after weight loss in obese subjects: a predisposing factor for relapse of obesity?. Am J Clin Nutr 39 (1984) 380-387
85. Golay A., Schutz Y., Broquet C., Moeri R., Felber J.P., and Jéquier E. Decreased thermogenic response to an oral glucose load in older subjects. J Am Geriatr Soc 31 (1983) 144-148
86. Landsberg L., Young J.B., Leonard W.K., Lisenmeire R.A., and Turek F.W. Is obesity associated with lower body temperatures? Core temperature: a forgotten variable in energy balance. Metab Clin Exp 58 (2009) 871-876
87. Mellen P.B., Gao S.K., Vitolins M.Z., and Goff Jr. D.C. Deteriorating eietary habits among adults with hypertension. DASH dietary accordance, NHANES 1988-1994 and 1999-2004. Arch Intern Med 168 (2008) 308-314
88. Mulrow C.D., Chiquette E., Angel L., Grimm R., Cornell J., Summerbell C.D., et al. WITHDRAWN: dieting to reduce body weight for controlling hypertension in adults. Cochrane Database Syst Rev 4 (2008) CD 000484
89. Kannel W.B., Brand N., Skinner Jr. J.J., Dawber T.R., and McNamara P.M. The relation of adiposity to blood pressure and development of hypertension. The Framingham study. Ann Intern Med 67 (1967) 48-59
90. Julius S., Valentini M., and Palatini P. Overweight and hypertension: a 2-way street?. Hypertension 35 (2000) 807-813
91. Kawasaki T., Uezono K., Sanefuji M., Utsunomiya H., Fujino T., Kanaya S., et al. A 17-year follow-up study of hypertensive and normotensive male university students in Japan. Hypertens Res 26 (2003) 445-452
92. Jose A.D., and Collison D. The normal range and determinants of the intrinsic heart rate in man. Cardiovasc Res 4 (1970) 160-167
93. Glick G., and Braunwald E. Relative roles of the sympathetic and parasympathetic nervous systems in the reflex control of heart rate. Circ Res 16 (1965) 363-375
94. Fagard R.H., Stolarz K., Kuznetsova T., Seidlerova J., Tikhonoff V., Grodzicki T., et al. Sympathetic activity, assessed by power spectral analysis of HR variability, in white-coat, masked, and sustained hypertension versus true normotension. J Hypertens 25 (2007) 2280-2285
95. Carmelli D., Robinette D., and Fabsitz R. Concordance, discordance and prevalence of hypertension in World War II. J Hypertens 12 (1994) 323-328
96. Flaa A., Eide I.K., Kjeldsen S.E., and Rostrup M. Sympathoadrenal stress reactivity is a predictor of future blood pressure: an 18-year follow-up study. Hypertension 52 (2008) 336-341
97. Masuo K., Mikami H., Ogihara T., and Tuck M.L. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. Am J Hypertens 10 (1997) 77-83
98. Masuo K., Kawaguchi H., Mikami H., Ogihara T., and Tuck M.L. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 42L (2003) 474-480
99. Flaa A., Sandvik L., Kjeldsen S.E., Eide I.K., and Rostrup M. Does sympathoadrenal activity predict changes in body fat? An 18-y follow-up study. Am J Clin Nutr 87 (2008) 1596-1601
100. Bertel O., Bühler F.R., Kiowski W., and Lütold B.E. Decreased beta-adrenoreceptor responsiveness as related to age, blood pressure, and plasma catecholamines in patients with essential hypertension. Hypertension 2 (1980) 130-138
101. Jennings G., Bobik A., Esler M., and Korner P. Contribution of cardiovascular reflexes to differences in beta-adrenoceptor-mediated responses in essential hypertension. Clin Sci 61 Suppl 7 (1981) 177s-180s
102. Volpe M., Trimarco B., Ricciardelli B., Rengo F., Chiariello M., Cuocolo A., et al. Effects of salt loading on the response to isoproterenol in normal and hypertensive subjects. Cardiologia 27 (1982) 453-461
103. Feldman R.D., and Chorazyczewski J. G-protein function is reduced in hypertension. Hypertension 29 (1997) 422-427
104. Valentini M., Julius S., Palatini P., Brook R.D., Bard R.L., Bisognano J.D., and Kaciroti N. Attenuation of haemodynamic, metabolic and energy expenditure responses to isoproterenol in patients with hypertension. J Hypertens 22 (2004) 1999-2006
105. Julius S., and Jamerson K. Sympathetics insulin resistance and coronary risk in hypertension: the "chicken-and-egg" question. J Hypertens 12 (1994) 495-502
106. Lowell B.B., and Bachman E.S. β-adrenergic receptors, diet-induced thermogenesis, and obesity. J Biol Chem 278 (2003) 29385-29388
107. Green S.A., Cole G., Jacinto M., Innis M., and Ligget S.B. A polymorphism of the human beta2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 268 (1993) 23116-23121
108. Reihsaus E., Innis M., MacIntyre N., and Ligget S.B. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 8 (1993) 334-339
109. Kotanko P., Ho{combining double acute accent}linger O., and Skrabat F. β-2 adrenoceptor density in fibroblast culture correlates with human NaCl sensitivity. Am J Physiol 263 (1992) C623-C627
110. Svetkey L.P., Chen Y.-T., Mckeown S.P., Preis L., and Wilson A.F. Preliminary evidence of linkage of salt sensitivity in black Americans at the β-2 adrenergic receptor locus. Hypertension 29 (1997) 918-922
111. Kotanko P., Binder A., Tasker J., Defreitas P., Kamdar S., Clark A.J.L., et al. Essential hypertension in African Caribbean associates with a variant of the β2-adrenoceptor. Hypertension 30 (1997) 773-776
112. Timmermann B., Mo R., Luft F.C., Gerdts E., Busjahn, Omvik P., et al. β-2 Adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: the Bergen Blood Pressure Study. Kidney Int 53 (1998) 1455-1460
113. Gratze G., Fortin J., Labugger R., Binder A., Kotanko P., Timmermann B., et al. B-2 adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Hypertension 33 (1999) 1425-1430
114. Busjahn A., Li G.-H., Faulhaber H.-D., Rosenthal M., Becker A., Jeschke E., et al. β2-adrenergic receptor gene variations, blood pressure, and heart size in normal twins. Hypertension 35 (2000) 555-560
115. Bengtsson K., Orho-Melander M., Melander O., Lindblad U., Ranstam J., Ranstam L., et al. β2-adrenergic receptor gene variation and hypertension in subjects with type 2 diabetes. Hypertension 37 (2001) 1303-1308
116. Castellano M., Rossi F., Giacchè M., Perani C., Rivadosi F., and Muiesan M.L. β2- adrenergic receptor gene polymorphism, age, and cardiovascular phenotypes. Hypertension 41 (2003) 361-367
117. Pereira A.C., Floriano M.S., Mota G.F.A., Cunha R.D., Herkenhoff F.L., Mill J.G., et al. β2 adrenoceptor functional gene variants, obesity, and blood pressure level interactions in the general population. Hypertension 42 Part 2 (2003) 685-692
118. Masuo K., Katsuya T., Fu X., Rakugi H., Ogihara T., and Tuck M. β2- and β3- adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years. Circulation 11 (2005) 3429-3434
119. Eisenach J.H., Schroeder D.R., Pike T.L., Johnson C.P., Schrage W.G., Snyder E.M., et al. Dietary sodium restriction and beta-2 adrenergic receptor polymorphism modulate cardiovascular function in humans. J Physiol 574 (2006) 955-965
120. Masuo K., Katsuya T., Kawaguchi H., Fu Y., Rakugi H., Ogihara T., and Tuck M.L. Rebound weight gain as associated with high plasma norepinephrine levels that are mediated through polymorphisms in the beta2-adrenergic receptor. Am J Hypertens 18 (2005) 1508-1516
121. Kawaguchi H., Masuo K., Katsuya T., Sugimoto K., Rakugi H., Ogihara T., et al. β2- and β3-adrenoceptor polymorphisms relate to subsequent weight gain and blood pressure elevation in obese normotensive individuals. Hypertens Res 29 (2006) 951-959
122. Garovic V.D., Joyner M.J., Dietz N.M., Boerwinkle E., and Turner S.T. β2- adrenergic receptor polymorphism and nitric oxide-dependent forearm blood flow responses to isoproterenol in humans. J Physiol 546 (2003) 583-589
123. Narkiewicz K., and Somers V.K. The sympathetic nervous system and obstructive sleep apnea: implications for hypertension. J Hypertens 15 (1997) 1613-1619
124. Somers V.K., Dyken M.E., Clary M.P., and Abboud F.M. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 96 (1995) 1897-1904
125. Kraiczi H., Hedner J., Peker Y., and Carlson J. Increased vasoconstrictor sensitivity in obstructive sleep apnea. J Appl Physiol 89 (2000) 493-498
126. Fletcher E.C. Sympathetic over activity in the etiology of hypertension of obstructive sleep apnea. Sleep 1 (2003) 15-19
127. Mortimore I.L., Marshall I., Wraith P.K., Sellar R.J., and Douglas N.J. Neck and total body fat deposition in nonobese and obese patients with sleep apnea compared with that in control subjects. Am J Respir Crit Care Med 157 (1998) 280-283
128. Grassi G., Facchini A., Trevano F.Q., Dell'Oro R., Arenare F., Tana F., et al. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 46 (2005) 321-325
129. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 373 (1994) 425-432
130. Haynes W.G. Role of leptin in obesity-related hypertension. Exp Physiol 90 (2005) 683-688
131. Eikelis N., Schlaich M., Aggarwal A., Kaye D., and Esler M. Interactions between leptin and the human sympathetic nervous system. Hypertension 41 (2003) 1072-1079
132. Gusmao Correia M.L., and Haynes W.G. Leptin, obesity and cardiovascular disease. Curr Opin Nephrol Hypertens 13 (2004) 215-223
133. Jackson E.K., and Li P. Human leptin has natriuretic activity in the rat. Am J Physiol 272 (1997) F333-F338
134. Hall J.E., Hildebrandt D.A., and Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens 14 (2001) 103S-115S
135. Carlyle M., Jones O.B., Kuo J.J., and Hall J.E. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension 39 (2002) 496-501
136. Kim S., Whelan J., Claycombe K., Reath D.B., and Moustaid-Moussa N. Angiotensin II increases leptin secretion by 3T3-L1 and human adipocytes via a prostaglandin-independent mechanism. J Nutr 132 (2002) 1135-1140
137. Frühbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes 48 (1999) 903-908
138. Nakagawa K., Higashi Y., Sasaki S., Oshima T., Matsuura H., and Chayama K. Leptin causes vasodilation in humans. Hypertens Res 25 (2002) 161-165
139. Gardiner S.M., Kemp P.A., March J.E., and Bennett T. Regional haemodynamic effects of recombinant murine or human leptin in conscious rats. Br J Pharmacol 130 (2000) 805-810
140. Rahmouni K., Jalali A., Morgan D.A., and Haynes W.G. Lack of dilator effect of leptin in the hindlimb vascular bed of conscious rats. Eur J Pharmacol 518 (2005) 175-181
141. Scherer P.E., Williams S., Fogliano M., Baldini G., and Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270 (1995) 26746-26749
142. Maeda K., Okubo K., Shimomura I., Funahashi T., Matsuzawa Y., and Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221 (1996) 286-289
143. Côté M., Mauriège P., Bergeron J., Alméras N., Tremblay A., Lemieux I., et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 90 (2005) 1434-1439
144. Imatoh T., Miyazaki M., Momose Y., Tanihara S., and Une H. Adiponectin levels associated with the development of hypertension: a prospective study. Hypertens Res 31 (2008) 229-233
145. Li H.Y., Chiu Y.F., Hwu C.M., Sheu W.H., Hung Y.J., Fujimoto W., et al. The negative correlation between plasma adiponectin and blood pressure depends on obesity: a family-based association study in SAPPHIRe. Am J Hypertens 21 (2008) 471-476
146. Tanida M., Shen J., Horii Y., Matsuda M., Kihara S., Funahashi T., et al. Effects of adiponectin on the renal sympathetic nerve activity and blood pressure in rats. Exp Biol Med (Maywood) 232 (2007) 390-397
147. Hoyda T.D., Smith P.M., and Ferguson A.V. Adiponectin acts in the nucleus of the solitary tract to decrease blood pressure by modulating the excitability of neuropeptide Y neurons. Brain Res 1256 (2009) 76-84
148. Nowak L., Adamczak M., and Wiecek A. Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 18 (2005) 1470-1475
149. Barton D.A., Dawood T., Lambert E.A., Esler M.D., Haikerwal D., Brenchley C., et al. Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk?. J Hypertens 25 (2007) 2117-2124
150. Lambert E., Hotchkin E., Alvarenga M., Pier C., Richards J., Barton D., et al. Single-unit analysis of sympathetic nervous discharges in patients with panic disorder. J Physiol 570 (2006) 637-643
151. Julius S., and Nesbitt S. Clinical consequences of the autonomic imbalance in hypertension and congestive heart failure. Scand Cardiovasc J Suppl 47 (1998) 23-30
152. Bakris G.L., Hart P., and Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int 70 (2006) 1905-1913
153. Sharma A.M., Pischon T., Hardt S., Kunz I., and Luft F.C. Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 37 (2001) 250-254
154. Messerli F.H., Bell D.S., Fonseca V., Katholi R.E., Mc Gll J.B., Phillips R.A., et al. Body weight changes with beta-blocker use: results from GEMINI. Am J Med 120 (2007) 610-615
155. Wofford M.R., Anderson D.C., Brown C.A., Jones D.W., Miller M.E., and Hall J.E. Antihypertensive effect of alpha and beta adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 14 (2001) 694-698
156. Reisin E., and Jack A.V. Obesity and hypertension: mechanisms, cardio-renal consequences, and therapeutic approaches. Med Clin North Am 93 (2009) 733-751
157. Redon J., Cifkova R., Laurent S., Nilsson P., Narkiewicz K., Erdine S., and Mancia G. Scientific Council of the European Society of Hypertension. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens 26 (2008) 1891-1900